PT  - JOURNAL ARTICLE
AU  - Campbell, Cori
AU  - Wang, Tingyan
AU  - Smith, David A
AU  - Freeman, Oliver
AU  - Noble, Theresa
AU  - Várnai, Kinga A
AU  - Harris, Steve
AU  - Salih, Hizni
AU  - Roadknight, Gail
AU  - Little, Stephanie
AU  - Glampson, Ben
AU  - Mercuri, Luca
AU  - Papadimitriou, Dimitri
AU  - Jones, Christopher R
AU  - Taylor, Vince
AU  - Chaudhry, Afzal
AU  - Phan, Hang
AU  - Borca, Florina
AU  - Olza, Josune
AU  - Warricker, Frazer
AU  - Romão, Luis
AU  - Ramlakhan, David
AU  - English, Louise
AU  - Klenerman, Paul
AU  - Andersson, Monique I.
AU  - Collier, Jane
AU  - Nastouli, Eleni
AU  - Khakoo, Salim I
AU  - Gelson, William
AU  - Cooke, Graham S
AU  - Woods, Kerrie
AU  - Davies, Jim
AU  - Barnes, Eleanor
AU  - Matthews, Philippa C
TI  - Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK
AID  - 10.1101/2021.11.10.21265651
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.10.21265651
4099  - http://medrxiv.org/content/early/2021/11/11/2021.11.10.21265651.short
4100  - http://medrxiv.org/content/early/2021/11/11/2021.11.10.21265651.full
AB  - Background and aims To determine the impact of the COVID-19 pandemic on the population with chronic Hepatitis B virus (HBV) infection under hospital follow-up in the UK, we quantified the coverage and frequency of measurements of biomarkers used for routine surveillance (ALT and HBV viral load).Methods We used anonymised electronic health record data from the National Institute for Health Research (NIHR) Health Informatics Collaborative (HIC) pipeline representing five UK NHS Trusts.Results We report significant reductions in surveillance of both biomarkers during the pandemic compared to pre-COVID years, both in terms of the proportion of patients who had ≥1 measurement annually, and the mean number of measurements per patient.Conclusions Further investigation is required to determine whether these disruptions will be associated with increased rates of adverse chronic HBV outcomes.Competing Interest StatementConflict of interest statement: GC reports personal fees from Gilead and Merck Sharp & Dohme outside the submitted work. BG reports other from Imperial National Institute for Health Research (NIHR) Biomedical Research Centres (BRC), during the conduct of the study. EN reports grants from ViiV healthcare, grants from GlaxoSmithKline (GSK), grants from Gilead, outside the submitted work. Other authors have no conflict of interest. Financial support statement: This work has been conducted using National Institute for Health Research (NIHR) Health Informatics Collaborative (HIC) data resources and funded by the NIHR HIC, and has been supported by NIHR Biomedical Research Centres at Cambridge, Imperial, Oxford, Southampton, and University College London Hospitals. GSC is an NIHR research professor, EB is an NIHR senior investigator. PCM is funded by the Wellcome Trust (ref. 110110/Z/15/Z) and holds an NIHR Senior Fellowship award. CC is a doctoral student who receives partial doctoral funding from GlaxoSmithKline (GSK). FW is an NIHR funded ACF. The views expressed in this letter are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health. Funding StatementFinancial support statement: This work has been conducted using National Institute for Health Research (NIHR) Health Informatics Collaborative (HIC) data resources and funded by the NIHR HIC, and has been supported by NIHR Biomedical Research Centres at Cambridge, Imperial, Oxford, Southampton, and University College London Hospitals. GSC is an NIHR research professor, EB is an NIHR senior investigator. PCM is funded by the Wellcome Trust (ref. 110110/Z/15/Z) and holds an NIHR Senior Fellowship award. CC is a doctoral student who receives partial doctoral funding from GlaxoSmithKline (GSK). FW is an NIHR funded ACF. The views expressed in this letter are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval: The research database for the NIHR HIC viral hepatitis theme was approved by South Central - Oxford C Research Ethics Committee (REF Number: 21/SC/0060). All methods in this study were carried out in accordance with relevant guidelines and regulations. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study utilised routinely-collected individual-level secondary care data (including demographic and laboratory parameters) collected across NHS Trusts in England by the National Institute for Health Research (NIHR) Health Informatics Collaborative (HIC), as previously described (1,2). The NIHR Health Informatics Collaborative (HIC) is a partnership of 29 NHS trusts and health boards, including the 20 hosting NIHR Biomedical Research Centres (BRCs), working together to facilitate the equitable re-use of NHS data for translational research. The NIHR HIC has established cross-site data collaborations in areas such as cardiovascular medicine, critical care, renal disease, infectious diseases, and cancer. All data analysed in the present study are part of the NIHR HIC database.ALTAlanine transferaseCHBChronic HBVCOVID-19Coronavirus Disease 2019GHSSGlobal Health Sector StrategyHBVHepatitis B virusHCCHepatocellular carcinomaHICHealth Informatics CollaborativeNHSNational Health ServiceNIHRNational Institute for Health ResearchSARS-CoV-2Severe acute respiratory syndrome coronavirus 2VLViral loadWHOWorld Health Organization